Among the major subgroups, ETV6-RUNX1 patients had the fastest disease clearance, with 36% (245 of 675) having undetectable MRD, whereas CYTO-HR/T-ALL patients recorded the slowest disease clearance (Figs 1C and 1D and Appendix Table A1). This evidence concerns the gene RUNX1 and acute lymphoblastic leukemia.